Concise Review: Precision Matchmaking: Induced Pluripotent Stem Cells Meet Cardio‐Oncology

As common chemotherapeutic agents are associated with an increased risk of acute and chronic cardiovascular complications, a new clinical discipline, cardio‐oncology, has recently emerged. At the same time, the development of preclinical human stem cell‐derived cardiovascular models holds promise as a more faithful platform to predict the cardiovascular toxicity of common cancer therapies and advance our understanding of the underlying mechanisms contributing to the cardiotoxicity. In this article, we review the recent advances in preclinical cancer‐related cardiotoxicity testing, focusing on new technologies, such as human induced pluripotent stem cell‐derived cardiomyocytes and tissue engineering. We further discuss some of the limitations of these technologies and present future directions. stem cells translational medicine 2019;8:758&767